If you have tried multiple anti-depressants with inadequate results, OR if you prefer a non-medicated and non-invasive treatment for depression without the harsh side effects of drugs, then dTMS (Deep Transcranial Magnetic Stimulation) treatment may be for you.
Achieve TMS is the nation’s largest dTMS treatment provider, treating over 600 patients to date.
Achieve TMS is the leading provider of Deep Transcranial Magnetic Stimulation depression treatments. With over 600 patients treated and countless success stories, we’ve brought hope back to those who have been suffering in silence.
PHQ-9 Depression Screening
Achieve TMS offers an online version of the commonly used Depression Screening tool called the PHQ-9. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
It is a technology that is similar to what is used in MRI (magnetic resonance imaging systems). dTMS is widely tested, participating in over 60 clinical trials worldwide with registered patents by the U.S. National Institutes of Health (NIH).
FDA-approved dTMS depression treatments are administered by Certified Technicians. Data has also been submitted to the FDA for dTMS in the treatment of OCD.
Oscar G. Morales, MD, is Senior Medical Advisor for Achieve TMS since 2017. Dr. Morales is the founder (2009) and medical director of the McLean Hospital TMS Service, the first in the Harvard Medical School and Partners Healthcare system dedicated to psychiatric treatments and investigation. He is responsible for all TMS activities including clinical, training, and current investigation of TMS in treating psychiatric disorders.
Within the MGH/McLean Adult Psychiatry Residency Training Program, Dr. Morales is part of the faculty and is involved in the training of Harvard students, residents, fellows, and psychiatrists. He was involved in the efforts that led Massachusetts Medicare to approve TMS for depression and soon after with the largest private health insurance companies.